NevGold Announces C$10M Brokered Private Placement Financing

Executive Summary

• NevGold Corp. entered into an agreement with Clarus Securities Inc. to act as sole agent and bookrunner for a best‑efforts private placement of units at $0.65 per unit, targeting gross proceeds of up to $10 million.
• Each unit consists of one common share and half of a common‑share purchase warrant (full warrant exercisable at $0.90 per share for 24 months, with an exercise restriction expiring 61 days after closing).
• Net proceeds are earmarked to advance the Limousine Butte gold‑antimony project (Nevada), Nutmeg Mountain gold project (Idaho), Zeus copper project (Idaho), as well as for working capital and general corporate purposes.

Key Details

• Issue Price: $0.65 per unit
• Maximum Gross Proceeds: Up to $10 million (within Listed Issuer Financing Exemption limits)
• Unit Composition: 1 common share + ½ of a common‑share purchase warrant (full warrant exercisable at $0.90 for 24 months)
• Warrant Exercise Restriction: Cannot be exercised until 61 days after the Closing Date
• Agent Compensation:
• 7.0% cash commission on gross proceeds
• 7.0% non‑transferable compensation options (each option allows purchase of one common share at $0.65 for 24 months)
• Closing Anticipated: On or about November 27, 2025, subject to required approvals (including TSX Venture Exchange).
• Use of Proceeds:
• Advancement of Limousine Butte gold‑antimony project (Nevada)
• Development of Nutmeg Mountain gold project (Idaho)
• Development of Zeus copper project (Idaho)
• Working capital and general corporate purposes
• Offering Eligibility: Units offered to Canadian residents outside Quebec and other qualifying jurisdictions under the Listed Issuer Financing Exemption (NI 45‑106). No hold period applies.
• Regulatory Notices: Securities not registered under the U.S. 1933 Act; cannot be sold in the United States except pursuant to applicable exemptions.

Notable Quotes

“Signed” – Brandon Bonifacio, President & CEO

All forward‑looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed.